Want to see JP:5592 full AI Analyst Report?
5592 Stock Chart & Stats
¥2661.00
-¥9.00(-0.63%)
At close: 4:00 PM EST
¥2661.00
-¥9.00(-0.63%)
Day’s Range― - ―
52-Week Range¥2,065.00 - ¥4,685.00
Previous CloseN/A
Volume47.70K
Average Volume (3M)73.92K
Market Cap
¥24.11B
Enterprise Value¥26.83B
Total Cash (Recent Filing)¥1.89B
Total Debt (Recent Filing)¥56.01M
Price to Earnings (P/E)8.4
Beta0.80
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.03%
Share Statistics
EPS (TTM)197.55
Shares Outstanding11,459,482
10 Day Avg. Volume72,500
30 Day Avg. Volume73,916
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.41
Price to Sales (P/S)2.22
P/FCF Ratio9.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)188.9
Revenue Forecast (FY)¥14.30B
Bulls Say, Bears Say
Bulls Say
Strong Multi-year Revenue And Profit GrowthSustained top-line and net-income expansion over 2022–2026 indicates scalable demand and improving unit economics. This multi-year growth trajectory supports reinvestment in the platform, strengthens operating leverage, and underpins durable earnings power across the 2–6 month horizon.
Platform Business In Healthcare And PharmaciesA digital healthcare/pharmacy platform benefits from structural industry tailwinds (digitalization, convenience) and potential network effects between consumers and pharmacies. Platform workflows and recurring engagements support durable revenue streams and higher customer retention over the medium term.
Strengthened Equity And Improved Returns On CapitalMaterial equity growth and elevated ROE indicate stronger capitalization and effective capital deployment. A beefed-up equity base improves balance-sheet resilience, supports additional investment or weathering shocks, and reduces the likelihood of forced external financing over the medium term.
Bears Say
Major 2025 Cash-flow OutflowA severe cash outflow in 2025, contrasting with positive earnings, signals volatile cash quality and potential working-capital or one-off investment risks. Such swings can force external funding, stress liquidity management, and impair predictability of free-cash-flow generation in the medium term.
Volatile Leverage And Asset BaseWide swings in debt and total assets indicate inconsistent capital structure and possible balance-sheet restructurings. This volatility reduces forecast reliability, raises refinancing and covenant risks, and complicates assessment of sustainable leverage and funding needs over the coming months.
Limited Visibility On 2026 Margins And Reporting ConsistencyLack of detailed margin disclosure for the latest year and noted inconsistencies in growth figures impair assessment of profit quality. Without clear segment or margin data, it's harder to validate sustainability of 2026 earnings and to model near-term margin durability for planning.
Kusurinomadoguchi, Inc. News
5592 FAQ
What was Kusurinomadoguchi, Inc.’s price range in the past 12 months?
Kusurinomadoguchi, Inc. lowest stock price was ¥2065.00 and its highest was ¥4685.00 in the past 12 months.
What is Kusurinomadoguchi, Inc.’s market cap?
Kusurinomadoguchi, Inc.’s market cap is ¥24.11B.
When is Kusurinomadoguchi, Inc.’s upcoming earnings report date?
Kusurinomadoguchi, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 44 days.
How were Kusurinomadoguchi, Inc.’s earnings last quarter?
Kusurinomadoguchi, Inc. released its earnings results on May 14, 2026. The company reported ¥73.87 earnings per share for the quarter, beating the consensus estimate of N/A by ¥73.87.
Is Kusurinomadoguchi, Inc. overvalued?
According to Wall Street analysts Kusurinomadoguchi, Inc.’s price is currently Overvalued.
Does Kusurinomadoguchi, Inc. pay dividends?
Kusurinomadoguchi, Inc. pays a Notavailable dividend of ¥40 which represents an annual dividend yield of 1.03%. See more information on Kusurinomadoguchi, Inc. dividends here
What is Kusurinomadoguchi, Inc.’s EPS estimate?
Kusurinomadoguchi, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kusurinomadoguchi, Inc. have?
Kusurinomadoguchi, Inc. has 11,459,482 shares outstanding.
What happened to Kusurinomadoguchi, Inc.’s price movement after its last earnings report?
Kusurinomadoguchi, Inc. reported an EPS of ¥73.87 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.51%.
Which hedge fund is a major shareholder of Kusurinomadoguchi, Inc.?
Currently, no hedge funds are holding shares in JP:5592
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kusurinomadoguchi, Inc.
Kusurinomadoguchi, Inc., established in 2004 and headquartered in Tokyo, Japan, develops and implements a diverse array of technology solutions specifically designed for pharmacies and the wider medical care sector throughout the country. Its comprehensive platform includes patient-facing services such as the EPARK drug counter, an online portal for locating and booking appointments at pharmacies, and the EPARK medicine notebook, which enables digital management of family prescriptions and reservation for medication dispensations. The company also offers a dedicated site facilitating telephone medical consultations for over-the-counter medicines, alongside a system allowing patients to select their preferred pharmacy for services, and provides online medication guidance as well as hospital-supported online consultations. For pharmacy operations and management, Kusurinomadoguchi delivers Health Tech Navi, an electronic medication history system, and the Care Daisy system, which integrates various recording tools and ICT devices. It further provides procurement solutions for pharmaceuticals, including a marketplace for dispensing pharmacies to efficiently buy and sell surplus or slow-moving inventory, extending to the management and acquisition of otherwise stagnant stock. The firm also features a centralized management system to streamline outpatient reception, appointment scheduling, and online medical treatments. Additionally, it offers Pharmacy Support, a robust customer relationship management (CRM) system tailored for engaging repeat patients, alongside specialized operational systems for dispensing pharmacies and a matching service connecting nursing care facilities with appropriate pharmacies.
Technical Analysis
Options Prices
Currently, No data available
---